Black Rock Inc. Acelrx Pharmaceuticals Inc Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.2 - $0.35 $3,997 - $6,995	19,986 Added 1.04%	1,947,140 $407,000
Q2 2022 Aug 12, 2022	SELL	$0.18 - $0.29 $52,354 - $84,348	-290,856 Reduced 13.11%	1,927,154 $471,000
Q1 2022 May 12, 2022	SELL	$0.28 - $0.61 $1,642 - $3,577	-5,865 Reduced 0.26%	2,218,010 $633,000
Q4 2021 Feb 10, 2022	SELL	$0.49 - $1.02 $7,991 - $16,636	-16,310 Reduced 0.73%	2,223,875 $1.25 Million
Q3 2021 Nov 09, 2021	SELL	$0.93 - $1.51 $24,045 - $39,041	-25,855 Reduced 1.14%	2,240,185 $2.29 Million
Q2 2021 Aug 11, 2021	BUY	$1.03 - $1.7 $2.33 Million - $3.85 Million	2,266,040 New	2,266,040 $3.13 Million

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.